<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6123">
  <stage>Registered</stage>
  <submitdate>14/09/2016</submitdate>
  <approvaldate>14/09/2016</approvaldate>
  <nctid>NCT02905266</nctid>
  <trial_identification>
    <studytitle>A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma</studytitle>
    <scientifictitle>Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001941-26</secondaryid>
    <secondaryid>CA209-742</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Nivolumab
Other interventions - Ipilimumab

Experimental: Nivolumab and Ipilimumab Concomitant Administration - Followed by Nivolumab monotherapy

Experimental: Nivolumab and Ipilimumab Sequential Administration - Followed by Nivolumab monotherapy


Other interventions: Nivolumab
-Specified dose on specified days

Other interventions: Ipilimumab
-Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries) - Broad Scope</outcome>
      <timepoint>Up to 13 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of adverse events in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries) - Narrow Scope</outcome>
      <timepoint>Up to 13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of events within the hypersensitivity/infusion reaction select Adverse Events (AEs)category</outcome>
      <timepoint>Up to 13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of grade 3-5 AEs</outcome>
      <timepoint>Up to 13 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>Up to 36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Up to 36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK) as measured using serum concentration-time data.</outcome>
      <timepoint>Up to 13 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Males and Females, ages 15 years = of age (Except where local regulations and/or
             institutional policies do not allow for subjects &lt; 18 years of age to participate)

          -  Subjects must have been diagnosed with stage III or/and stage IV histologically
             confirmed melanoma that is unresectable or metastatic

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Subjects have not been treated by systemic anticancer therapy for unresectable or
             metastatic melanoma</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with active brain metastases or leptomeningeal metastases

          -  Subjects with ocular melanoma

          -  Subjects with active, known or suspected autoimmune disease

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>27/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>102</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/11/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Local Institution - North Sydney</hospital>
    <hospital>Local Institution - Greenslopes</hospital>
    <hospital>Cabrini Hospital - Malvern</hospital>
    <postcode>2060 - North Sydney</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Meldola (FC)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a safety and efficacy study of different administration regimens of nivolumab plus
      Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02905266</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>